Four checks keep your next hip visit clear

The clinic can name what it plans to use

Ask whether the treatment comes from your blood or another source. PRP means platelet-rich plasma. Staff draw your blood, spin it so more platelets collect in less liquid, then place that liquid in the hip. Have them write the treatment name down.

Next, ask whether the research was about hips. A result from knees doesn’t prove the same result in hips. The hip sits deeper in the body, and it hasn’t been studied as much. That makes a clear answer even more important.

A useful answer covers relief, limits, and cost

Ask how much the soreness might ease and how long that change might last. Nobody knows your result in advance. Some hip studies found no clear edge for PRP over salt water or other care. The research doesn’t prove that PRP will help your hip.

Then get the whole cost in writing. Check for separate charges for an X-ray, follow-up, or another treatment. You can take the price home before making up your mind. Don’t let a sales deadline hurry you.

A visit can narrow the choices when soreness stays

If your hip isn’t settling, QC Kinetix offers regenerative treatments, its name for non-surgical care such as PRP drawn from your blood. A medical provider, the person doing your exam, will ask about the ache and watch the hip move.

Now your questions matter. Ask why the provider thinks PRP suits your hip, what it can’t do, and when surgery deserves thought. A straight answer will say the hip research is limited. It won’t promise relief.

Bring your notes and write down the answers. You’re allowed to think after the visit. A choice made later at home still counts.

Sources

1. FDA's public list of licensed cellular and gene therapy products is the checkable answer to 'is this FDA-approved?'. A product not on that list, and not being administered under an active IND, is not an approved therapy however it is described in a brochure. For orthopedics the list is short and its cartilage entry is MACI, indicated for focal full-thickness knee defects.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Approved Cellular and Gene Therapy Products. FDA, 2026.

2. A 2025 review of mesenchymal stem cell injection research in orthopaedics identified 449 registered clinical trials, of which only 159 (35.4%) were complete and only 56 (12.5%) had published results in peer-reviewed journals. Hip and knee osteoarthritis were the most common indications (37.6%). Reported cell concentrations spanned three orders of magnitude and 55.5% of protocols did not specify a concentration at all.

   Bezuglov E, et al. — Mesenchymal stem cells injections in traumatology and orthopaedics: common practice or still a promising area with many uncertainties?. BMC Musculoskeletal Disorders, 2025. DOI: 10.1186/s12891-025-09123-8.

3. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446), and centres claimed a mean clinical efficacy of 82% (SD 9.6%) - a figure with no support in the published evidence. The gap between the quoted number and the trial data is the single most useful thing a patient can be told before a consultation.

   Piuzzi NS, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. The journal of knee surgery, 2018. DOI: 10.1055/s-0037-1604443.

4. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.